{"disease":{"id":"central-diabetes-insipidus","name":"central diabetes insipidus"},"drugs":{"marketed":[{"drug_id":"desmopressin","indication_name":"Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"lypressin","indication_name":"Partial Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lysipressin","generic_name":"LYPRESSIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Vasopressin receptor","drug_class":"lypressin","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"lysine","indication_name":"Partial Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"L-Lysine","generic_name":"LYSINE","company_name":"Advanced Accelerator Applications","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"lysine","quality_score":23,"revenue":null,"mechanism":""},{"drug_id":"minirin","indication_name":"Partial Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minirin","company_name":"Hormozgan University of Medical Sciences","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"desmopressin","indication_name":"Partial Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ddavp","generic_name":"DESMOPRESSIN","company_name":"Ferring Pharms Inc","drug_phase":"marketed","molecular_target":"Vasopressin V1b receptor","drug_class":"Factor VIII Activator","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"argipressin","indication_name":"Partial Central Diabetes Insipidus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Argipressin","company_name":"Kristina Svennerholm","drug_phase":"marketed","molecular_target":"Oxytocin receptor, Vasopressin V1a receptor, Vasopressin V1b receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03474601","title":"Seoul National University Pituitary Disease Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":1600,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04902235","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (CRH Study)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT04897802","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false},{"nct_id":"NCT05319301","title":"Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}